Trial Profile

A Phase 2 clinical trial of IGX12 in France

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 13 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IGX 12 (Primary)
Indications Infertility
Focus Adverse reactions; Therapeutic Use

Most Recent Events

13 Nov 2025 New trial record
02 Oct 2025 According to an Igyxos Biotherapeutics media release, company announced that it has secured a EUR 5.7 million grant under the France 2030 programme, via the Biotherapies and Bioproduction of Innovative Therapies call for projects (AAP), operated by Bpifrance on behalf of the French Government. The non-dilutive funding will support Phase 2 clinical trials, in France and Europe of IGX12.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com